Medical/Pharmaceuticals

Innovent and Etana Jointly Announce the Approval of Bevagen® (Bevacizumab Biosimilar) by the Indonesian Food and Drugs Authority (BPOM)

SAN FRANCISCO and SUZHOU, China, June 14, 2022 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high quality medicines for the treatment of oncology, autoimmune, metabolic, ophthalmology and...

2022-06-14 08:00 3603

Innovent Announces the NMPA Acceptance of the New Drug Application for Tafolecimab Injection (anti-PCSK-9 antibody)

SAN FRANCISCO and SUZHOU, China, June 14, 2022 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high-quality medicines for the treatment of oncology, autoimmune, metabolic, ophthalmology and...

2022-06-14 08:00 2459

Treadwell Announces Initiation of Patient Dosing in TWT-203, a Phase 1b/2 study of TTK Inhibitor, CFI-402257, in Patients with ER+/Her2- Breast cancer

NEW YORK and HONG KONG, June 14, 2022 /PRNewswire/ -- Treadwell Therapeutics, a clinical-stage biotechnology company developing novel medicines for unmet needs in cancer, today announced the initiation of patient dosing in TWT-203, its Phase1b/2 study to evaluate CFI-402257, an oral, best-in-clas...

2022-06-14 04:01 2260

Good News from Taiwan Participants in BIO 2022 - Pharmasaga and PrecisemAb Make It to the Start-Up Stadium Finalists Defeating Hundred Teams

TAIPEI, June 13, 2022 /PRNewswire/ -- As the post-pandemic era approaches, the biomedical industry has become a strategic domain of focal emphasis inTaiwan and would be the critical impetus for the next wave of growth. In order to step up international connection and strive for business opportuni...

2022-06-14 00:00 1883

Dompé Announces Results of Phase 2 Study Evaluating the Efficacy and Safety of Reparixin in Patients with Severe COVID-19 Pneumonia

* In hospitalized patients with COVID-19 Pneumonia, the rates of clinical events among those treated with Reparixin (n=36) were statistically significantly lower than standard of care (n=19). * The study is the first evaluation of the efficacy and safety of Reparixin an IL-8 inhibitor in pati...

2022-06-13 21:20 2733

META Pharmaceuticals, a pioneer biotech in immune-metabolism, raised 15M USD to accelerate its pipeline development

SHENZHEN, China, June 13, 2022 /PRNewswire/ -- Today, META Pharmaceuticals, China's first immunometabolism-based small-molecule drug discovery company, announced two consecutive Seed and Pre-A funding rounds totaling15 million USD. Investors include Forcefield Ventures, XtalPi Inc., IMO Ventures,...

2022-06-13 20:00 1987

Jubilant Radiopharma Joins Illuccix® Pharmacy Partner Network

MELBOURNE, Australia and INDIANAPOLIS, June 13, 2022 /PRNewswire/ -- Telix Pharmaceuticals Limited (ASX: TLX, Telix, the Company) is pleased to announce that its prostate cancer imaging agent, Illuccix® (kit for preparation of gallium Ga 68 gozetotide), is now available at selected pharmacies in ...

2022-06-13 19:11 1899

Novavax COVID-19 Vaccine Nuvaxovid™ Provisionally Registered in Australia as a Booster in Individuals Aged 18 and Over

* In Australia, Nuvaxovid™ is the first protein-based COVID-19 vaccine registered for use as a booster regardless of previous vaccine history GAITHERSBURG, Md., June 13, 2022 /PRNewswire/ -- Novavax, Inc. (NASDAQ: NVAX), a biotechnology company dedicated to developing and commercializing next-...

2022-06-13 19:00 2068

POSITIVE DATA FOR PAXALISIB IN TWO CHILDHOOD BRAIN CANCERS PRESENTED AT 20TH ISPNO ANNUAL MEETING

SYDNEY, June 13, 2022 /PRNewswire/ -- Kazia Therapeutics Limited (NASDAQ: KZIA; ASX: KZA), an oncology-focused drug development company, is pleased to announce the presentation of new data regarding the activity of paxalisib in two forms of childhood brain cancer with poor prognosis and limited t...

2022-06-13 19:00 3902

Curocell announced impressive CR rate in Phase 1 study with anbal-cel, the next generation CD19 CAR-T integrated OVIS™ platform

-  82% ORR (9 of 11 patients) and 82% (9 of 11 patients) CR rate documented after  anbal-cel treatment to the patients in relapsed/refractory large B-cell lymphoma -  2 out of 3 patients dosed with 2x105 cells/kg of anbal-cel lasting the complete response for more than 12 months -  Well tolerat...

2022-06-13 19:00 1547

Zhongchao Inc. Announces its MDMOOC Platform Launched Disease Prevention and Distribution Quality Management Course

SHANGHAI, June 13, 2022 /PRNewswire/ -- Zhongchao Inc. (NASDAQ: ZCMD) ("Zhongchao" or the "Company"), an internet technology company offering healthcare professionals the online healthcare information, professional training and educational services platform and patient management service, today ...

2022-06-13 18:30 1533

Smart Glove Lauded by Frost & Sullivan for Leading the Global Medical Gloves Industry with Pioneering Products and Creative Innovations

The company delivers a wide range of innovative and patented gloves to meet the growing demand worldwide. SAN ANTONIO, June 13, 2022 /PRNewswire/ -- Based on its recent analysis of the global medical gloves industry,Frost & Sullivan recognizes Smart Glove with the 2021 Technology Innovation Lead...

2022-06-13 17:27 1564

Meness Aptieka earns the Best Place to Work certification in Latvia for 2022

RIGA, Latvia, June 13, 2022 /PRNewswire/ -- Mēness Aptieka, one of the largest pharmacy brands inLatvia, has earned the best place to work certification in Latvia for its first participation. According to the assessment results, 81% of employees said that they are proud to work for the organizati...

2022-06-13 16:27 1191

Mentice AB explores the conditions for carrying out a directed share issue of approximately SEK 60 million

NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, IN OR INTOTHE UNITED STATES, AUSTRALIA, CANADA, NEW ZEALAND, JAPAN, SINGAPORE, SOUTH AFRICA, SOUTH KOREA, RUSSIA, BELARUS OR ANY OTHER JURISDICTION WHERE SUCH RELEASE, PUBLICATION OR DISTRIBUTION WOULD BE UN...

2022-06-13 15:40 1701

DoctorOnCall and BUMITRA Malaysia Seal Partnership to Encourage Vaccination Amongst Hajj & Umrah Pilgrims

KUALA LUMPUR, Malaysia, June 13, 2022 /PRNewswire/ -- Malaysian digital health platform, Health Digital Technologies Sdn. Bhd. (DoctorOnCall) has inked a Memorandum of Understanding (MoU) with Bumiputera Tourism Operators Association ofMalaysia (BUMITRA Malaysia) to facilitate and increase health...

2022-06-13 14:23 2349

General Homecare grows community of providers with the addition of NSW Home Support Services

* NSW Home Support Services joins General Homecare group * First non-Victorian brand to be part of General Homecare's "For locals, by locals" charter SYDNEY, June 13, 2022 /PRNewswire/ -- 30 May 2022, Melbourne. General Homecare, a leading homecare and Aged Care provider, has announced that N...

2022-06-13 09:00 2169

Kangpu Announces First Patient Dosed in the US Phase IIa Clinical Trial of NeoMIDES™ Molecular Glue KPG-818 in Systemic Lupus Erythematosus

SHANGHAI, June 12, 2022 /PRNewswire/ -- Kangpu Biopharmaceuticals, a clinical-stage company based inShanghai, China, announced today that the first patient has been dosed in the Company's US Phase IIa clinical trial of KPG-818, an orally bioavailable NeoMIDESTM molecular glue, for the treatment o...

2022-06-13 09:00 1508

Ascletis Announces Appointment of Mr. John P. Gargiulo, Former North America President and CEO of Daiichi Sankyo, as Chief Business Officer

HANGZHOU, China and SHAOXING, China, June 13, 2022 /PRNewswire/ -- Ascletis Pharma Inc. (HKEX: 1672, "Ascletis"), today announces the expansion of management team with appointment of Mr.John P. Gargiulo, former North America President and CEO of Daiichi Sankyo, as Chief Business Officer. Mr.John ...

2022-06-13 08:00 2079

Innovent and IASO Bio Present Updated Data of BCMA CAR-T Cell Therapy (Equecabtagene Autoleucel) at EHA 2022

SAN FRANCISCO and SUZHOU, China, June 13, 2022 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high-quality medicines for the treatment of oncology, autoimmune, metabolic, ophthalmology and...

2022-06-13 08:00 2510

Innovent Releases Results of High-dose Cohorts in Phase 1 Clinical Study of Mazdutide (IBI362) in Chinese Adults with Overweight or Obesity at ENDO 2022

SAN FRANCISCO and SUZHOU, China, June 13, 2022 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high-quality medicines for the treatment of oncology, metabolic, autoimmune, ophthalmology and...

2022-06-13 08:00 2729
1 ... 225226227228229230231 ... 573

Week's Top Stories